Stereotactic body radiotherapy to the lung primary lesion improves the survival of patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: A real-world study

被引：0

作者：

Wei, H. ^{[1
]}

Zhou, X. ^{[1
]}

Yang, H. ^{[1
]}

Gong, Y-L. ^{[2
,3
]}

Wang, J. ^{[1
]}

Xu, Y. ^{[1
]}

Zhou, L. ^{[1
]}

Xue, J. ^{[1
]}

Zou, B. ^{[4
]}

Zhang, Y. ^{[1
]}

Zhu, J. ^{[1
]}

Peng, F. ^{[1
]}

Huang, M. ^{[1
]}

Lu, Y. ^{[1
]}

Liu, Y. ^{[1
]}

机构：

[1] Sichuan Univ, Dept Thorac Oncol, West China Hosp, Chengdu, Peoples R China

[2] Sichuan Univ, Dept Thorac Oncol, Ctr Canc, West China Hosp, Chengdu, Peoples R China

[3] Sichuan Univ, West China Hosp, Ctr Canc, State Key Lab Biotherapy, Chengdu, Peoples R China

[4] Sichuan Univ, Sch Med, West China Hosp, Dept Thorac Oncol, Chengdu, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.1832

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1227P

引用

页码：S973 / S973

页数：1

共 50 条

[31] Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in non-small cell lung cancer: A real-world study.
Wu, Fang
Wu, Sixuan
Hu, Chunhong
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[32] EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer
Zhixin Sheng
Yanxia Zhang
Medical Oncology, 2015, 32
[33] First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence
Zhu, Zhouyu
Chai, Ying
CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 1667 - 1672
[34] Advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations: first-line treatment with afatinib and other EGFR TKIs
Brueckl, Wolfgang
Tufman, Amanda
Huber, Rudolf Maria
EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (02) : 143 - 155
[35] Efficacy Differences of First-line EGFR-TKIs Alone vs in Combination with Chemotherapy in Advanced Lung Adenocarcinoma Patients with Sensitive EGFR Mutation and Concomitant Non-EGFR Genetic Alterations
Guowei ZHANG
Ruirui CHENG
Yuanyuan NIU
Huijuan WANG
Xiangtao YAN
Mina ZHANG
Xiaojuan ZHANG
Jinpo YANG
Chunhua WEI
Zhiyong MA
中国肺癌杂志, 2022, (09) : 651 - 657
[36] Early Stereotactic Body Radiotherapy to the Primary Lung Lesion for Patients with Advanced NSCLC Treated with First-Line Systemic Therapy
Tao, D.
Sun, L.
Wang, L. L.
Yang, D.
Jiang, Y.
Zhou, W.
Wang, Y.
Wu, Y. Z.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2023, 117 (02): : S128 - S128
[37] Correlation Analysis between T790M Status and Clinical Characteristics of Patients with EGFR-sensitive Mutation Advanced NSCLC who Progressed after the First Generation and First-line EGFR-TKIs Administration: A Real-world Exploratory Study
Zhen, Ye
Xu, Ying-Bo
Deng, Ruo-Ying
Li, Meng
Ma, Min-Ting
Zhou, Zhi-Guo
Meng, Qing-Ju
Gong, Ya-Ning
Zhao, Li-Yan
Liu, Yi-Bing
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING, 2024, 27 (06) : 845 - 853
[38] Real-world data of first-line treatment with aumolertinib for elderly EGFR plus NSCLC patients
Zhang, H.
Cun, F. S.
ANNALS OF ONCOLOGY, 2022, 33 : S1586 - S1587
[39] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
Holleman, Marscha S.
Al, Maiwenn J.
Zaim, Remziye
Groen, Harry J. M.
Uyl-de Groot, Carin A.
EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01): : 153 - 164
[40] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
Marscha S. Holleman
Maiwenn J. Al
Remziye Zaim
Harry J. M. Groen
Carin A. Uyl-de Groot
The European Journal of Health Economics, 2020, 21 : 153 - 164

← 1 2 3 4 5 →